Operating characteristics of the Aspergillus GM EIA and BDG assay for surveillance testing in pediatric patients with cancer or undergoing HCT
| Author, year . | Study cohort size . | Study's IFD incidence rate . | Sensitivity . | Specificity . | PPV . | NPV . |
|---|---|---|---|---|---|---|
| Aspergillus GM EIA | ||||||
| Hovi et al34 | 98 | 8.0% | 93% | 50% | 14% | 99% |
| Steinbach et al35 | 64 | 0% | 87% | 0% | 0% | 98% |
| Hayden et al36 | 56 | 30.4% | 87% | 65% | 69% | 85% |
| Badiee et al37 | 62 | 16.1% | 92% | 90% | 82% | 96% |
| Koltze et al38 | 34 | 17.6% | 100% | 83% | 100% | 97% |
| Fisher et al26 | 425 | 0.7% | 0% | 98.8% | 0% | 99.9% |
| BDG assay | ||||||
| Badiee et al37 | 62 | 16.1% | 46% | 50% | 26% | 71% |
| Koltze et al38 | 34 | 17.6% | 29% | 83% | 20% | 89% |
| Fisher et al26 | 425 | 1.4% | 0% | 94.7% | 0% | 99.8% |
| Author, year . | Study cohort size . | Study's IFD incidence rate . | Sensitivity . | Specificity . | PPV . | NPV . |
|---|---|---|---|---|---|---|
| Aspergillus GM EIA | ||||||
| Hovi et al34 | 98 | 8.0% | 93% | 50% | 14% | 99% |
| Steinbach et al35 | 64 | 0% | 87% | 0% | 0% | 98% |
| Hayden et al36 | 56 | 30.4% | 87% | 65% | 69% | 85% |
| Badiee et al37 | 62 | 16.1% | 92% | 90% | 82% | 96% |
| Koltze et al38 | 34 | 17.6% | 100% | 83% | 100% | 97% |
| Fisher et al26 | 425 | 0.7% | 0% | 98.8% | 0% | 99.9% |
| BDG assay | ||||||
| Badiee et al37 | 62 | 16.1% | 46% | 50% | 26% | 71% |
| Koltze et al38 | 34 | 17.6% | 29% | 83% | 20% | 89% |
| Fisher et al26 | 425 | 1.4% | 0% | 94.7% | 0% | 99.8% |
Data in this table adapted from Lehrnbecher et al, Table 3.25